A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
- Resource Type
- Article
- Source
- In
Annals of Oncology October 2017 28(10):2533-2538 - Subject
- Language
- ISSN
- 0923-7534